search
Back to results

Stent Implantation of Polyurethane Expandable Valve, by Catheter, in Patients With Pulmonary Valve Dysfunction

Primary Purpose

Valvulopathy

Status
Not yet recruiting
Phase
Not Applicable
Locations
Brazil
Study Type
Interventional
Intervention
Polyurethane expandable valve stent implant
Sponsored by
Dr. Miguel Angel Maluf
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional device feasibility trial for Valvulopathy focused on measuring pulmonary valve dysfunction, pulmonary valvulopathy, Stent implant, Pulmonary valve disorders, Polyurethane Expandable Valve Stent, Tetralogy of Fallot, Cardiac insufficiency, right ventricular dysfunction, Pulmonary Valve Insufficiency, heart diseases, Prosthesis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients aged 18 years or older;
  • Pulmonary valve dysfunction and moderate to severe impairment of Right Ventricle function;
  • Functional Class II to IV New York Heart Association (NYHA) classification of heart failure.

Exclusion Criteria:

  • Impairment of cardiovascular function;
  • Neurological impairment;
  • Syndromes without prognosis or survival of less than 1 year;
  • Carriers of infection undergoing medical treatment;
  • Patients undergoing artificial life support;
  • Known hypersensitivity to aspirin or heparin;
  • Positive urine or serum test for pregnancy in female patients of reproductive age.

Sites / Locations

  • Hospital Alemão Oswaldo Cruz

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Polyurethane expandable valve stent implant surgery

Arm Description

Valve stent implantation will be performed under general anesthesia with transesophageal echocardiography monitoring, with thoracotomy approach median and circulation aid extracorporeal.

Outcomes

Primary Outcome Measures

Pulmonary Regurgitation After Polyurethane Expandable Valve Stent Implant Surgery
if there are changes in pulmonary regurgitation (PR): discreet or less (≤2+) on transthoracic echocardiogram (TTE).

Secondary Outcome Measures

Full Information

First Posted
March 11, 2022
Last Updated
March 21, 2022
Sponsor
Dr. Miguel Angel Maluf
Collaborators
SYNTHETIC HEART TECHNOLOGY
search

1. Study Identification

Unique Protocol Identification Number
NCT05289622
Brief Title
Stent Implantation of Polyurethane Expandable Valve, by Catheter, in Patients With Pulmonary Valve Dysfunction
Official Title
Single-arm Prospectus Study to Evaluate the Safety and Security of the Expandable Valve Stent, Approach Technique and Its Implantation in the Pulmonary Position
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 2022 (Anticipated)
Primary Completion Date
December 2022 (Anticipated)
Study Completion Date
February 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Dr. Miguel Angel Maluf
Collaborators
SYNTHETIC HEART TECHNOLOGY

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
Prospective Study, Single Arm to evaluate the safety and efficacy of polyurethane expandable valve implantation in the pulmonary position, in 5 patients over 18 years of age, with pulmonary valve dysfunction and moderate to severe impairment of Right Ventricular function. During throughout the study, safety parameters related to valve operation will be evaluated (patient's Functional Class), in addition to the occurrence of Serious Adverse Events. After the procedure, the patient must be hospitalized in the Intensive Care Unit until the complete hemodynamic stabilization and normalization of lung function and in good general condition (2 to 3 days of stay) and then transferred to the ward (2 to 3 days and stay) before hospital discharge. A formal Statistical Analysis Plan (SAP) will be developed and finalized before closing the database. Full details of data presentations and analysis will be provided in SAP. Additional statistical analyses, other than those described in this section, may be performed if deemed appropriate and included in SAP. Any deviations from the final analysis plan or what is presented in the protocol will be discussed in the final study report. No formal inferential statistics will be applied to the data collected in the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Valvulopathy
Keywords
pulmonary valve dysfunction, pulmonary valvulopathy, Stent implant, Pulmonary valve disorders, Polyurethane Expandable Valve Stent, Tetralogy of Fallot, Cardiac insufficiency, right ventricular dysfunction, Pulmonary Valve Insufficiency, heart diseases, Prosthesis

7. Study Design

Primary Purpose
Device Feasibility
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Prospective, Single Arm Safety and Efficacy Study to evaluate the expandable polyurethane valve in the pulmonary position, in 5 patients over 18 years of age, with pulmonary valve dysfunction and moderate to severe impairment of cardiac ventricular function.
Masking
None (Open Label)
Allocation
N/A
Enrollment
5 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Polyurethane expandable valve stent implant surgery
Arm Type
Experimental
Arm Description
Valve stent implantation will be performed under general anesthesia with transesophageal echocardiography monitoring, with thoracotomy approach median and circulation aid extracorporeal.
Intervention Type
Device
Intervention Name(s)
Polyurethane expandable valve stent implant
Intervention Description
The baseline assessment of patients will include the admission of patients and the performance of preoperative exams (cardiological imaging for the correct selection). An estimated surgery time of 5 hours. During the entire procedure, patients will be under general anesthesia and controlled mechanical ventilation. The material collected in the laboratory will be processed, the result released and discarded. After the patient enters the operating room, hemodynamic monitoring, ECG, arterial saturation, with peripheral sensor, central venous access with double lumen catheter will be carried out; blood pressure monitoring by radial artery puncture, bladder catheter and thermometer in the nasopharynx and rectum. After preoperative preparation, patients will undergo a surgical approach by median thoracotomy and installation of the Cardiopulmonary bypass (ECC) circuit, by placing a cannula in the ascending aorta, Superior Vena Cava (SVC) and Inferior Vena Cava (IVC).
Primary Outcome Measure Information:
Title
Pulmonary Regurgitation After Polyurethane Expandable Valve Stent Implant Surgery
Description
if there are changes in pulmonary regurgitation (PR): discreet or less (≤2+) on transthoracic echocardiogram (TTE).
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients aged 18 years or older; Pulmonary valve dysfunction and moderate to severe impairment of Right Ventricle function; Functional Class II to IV New York Heart Association (NYHA) classification of heart failure. Exclusion Criteria: Impairment of cardiovascular function; Neurological impairment; Syndromes without prognosis or survival of less than 1 year; Carriers of infection undergoing medical treatment; Patients undergoing artificial life support; Known hypersensitivity to aspirin or heparin; Positive urine or serum test for pregnancy in female patients of reproductive age.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Dayane Correa Vila Nova
Phone
+55 11 3549-0729
Email
dvilanova@haoc.com.br
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Miguel Angel Maluf
Organizational Affiliation
Hospital Alemão Oswaldo Cruz
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Alemão Oswaldo Cruz
City
São Paulo
ZIP/Postal Code
01327-001
Country
Brazil
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dayane Correa Vila Nova
Phone
+55 11 3549-0729
Email
dvilanova@haoc.com.br
First Name & Middle Initial & Last Name & Degree
Miguel Maluf

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
A representative appointed by the study sponsor, regulatory authorities, or other auditing bodies whose job it is to verify that the research is being conducted properly may review any study data and records maintained by the study physician at the research site only, maintaining the privacy and anonymity of each participant.

Learn more about this trial

Stent Implantation of Polyurethane Expandable Valve, by Catheter, in Patients With Pulmonary Valve Dysfunction

We'll reach out to this number within 24 hrs